Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Person

Nikhil Lalwani

Tracked across 2 events · 13 articles · First seen Apr 20, 2026 · Last active Sep 23, 2026

Sentiment
30
Attention
2
Events
2
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
1 50
Business
Impact: Nikhil Lalwani is CEO of ANI Pharmaceuticals; he commented on solid Q1 performance but was not directly involved in the stock sales.
Jul 09, 2026 · 6 articles
2 10
Regulatory
ANI Pharmaceuticals received final approval from the U.S. United States — Food and Drug Administration for its Abbreviated New Drug Application for Everolimus Tablets for Oral Suspension in 2mg, 3mg and 5mg strengths. The product…
Impact: As ANI's President and CEO, Nikhil Lalwani commented on the approval, highlighting the R&D team's execution and the company's target of launching at least 15 new generics in 2026.
Sep 23, 2026 · 7 articles
ERGEN INTELLIGENCE
Track Nikhil Lalwani live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.